Severity of Mitral Valve Degeneration Is Associated with Chromosome 15 Loci in Whippet Dogs by Stern, J A et al.
RESEARCH ARTICLE
Severity of Mitral Valve Degeneration Is
Associated with Chromosome 15 Loci in
Whippet Dogs
Joshua A. Stern1*, Weihow Hsue1, Kun-Ho Song1, Eric S. Ontiveros1, Virginia Luis
Fuentes2☯, Rebecca L. Stepien3☯
1 University of California Davis, Department of Medicine & Epidemiology, One Shields Ave, Davis,
California, 95616, United States of America, 2 Clinical Science and Services, Royal Veterinary College,
Hawkshead Lane, North Mymms, Hertfordshire, AL9 7TA, United Kingdom, 3 University of Wisconsin,
School of Veterinary Medicine, Department of Medical Sciences (Cardiology), 2015 Linden Drive, Madison,
Wisconsin, 53706, United States of America
☯ These authors contributed equally to this work.
* jstern@ucdavis.edu
Abstract
Mitral valve degeneration (MVD) is the most common form of heart disease in dogs, fre-
quently leading to left-sided congestive heart failure and cardiac mortality. Although breed-
specific disease characteristics and overrepresentation point towards a genetic origin for
MVD, a causative mutation and complete molecular pathogenesis are unknown. Whippet
dogs are overrepresented in incidence of MVD, suggesting an inherited component in this
breed. Expressivity of this condition is variable with some dogs showing evidence of more
severe disease at earlier ages than other dogs. This phenomenon makes a traditional case
versus control genetic study prone to phenotyping error. This study sought to avoid these
common pitfalls by identifying genetic loci associated with severity of MVD in Whippets
through a genome-wide association study (GWAS). 138Whippet dogs were characterized
for MVD by echocardiographic examination and a novel disease severity score was devel-
oped and adjusted for age in each subject. Single nucleotide polymorphism (SNP) genotype
data (170k Illumina CanineHD SnpChip) was obtained for DNA isolated from blood of each
study subject. Continuous variable genome wide association was performed after correc-
tion for population stratification by efficient mixed model association expedited (EMMAX) in
130 dogs. A genome wide significant association was identified on chromosome 15 (peak
locus 57,770,326; Padj = 0.049) and secondary loci of suggestive association were identified
on chromosome 2 (peak locus 37,628,875; Padj = 0.079). Positional candidate genes were
identified within the primary and secondary loci including follistatin-related protein 5 precur-
sor (FSTL5) and Rho GTPase-activating protein 26 (ARHGAP26). These results support
the hypothesis that severity of MVD in whippets has a genetic basis and warrants further
study by either candidate gene sequencing or next-generation techniques.
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Introduction
Mitral valve degeneration (MVD) is the most common form of heart disease in dogs, account-
ing for 75% of all dogs with cardiac disease [1]. The pathology of this disease in the dog resem-
bles that of primary mitral valve prolapse (MVP) of humans in some respects [2]. MVP is a
common cardiovascular abnormality, occurring in 2–8% of the human population [3]. In
humans, MVP is associated with clinically-important sequela, including mitral regurgitation,
bacterial endocarditis, congestive heart failure, atrial fibrillation, and sudden death [4].
In dogs, MVD is an acquired disease of advanced age [5]. The disease is characterized by
chronic progressive degenerative lesions of the mitral valve, where the valve leaflets become
thickened, develop poor coaptation, and may prolapse during systole into the left atrium [6].
These valve lesions result in mitral regurgitation, elevated left atrial pressure and, ultimately in
some dogs, left-sided congestive heart failure and cardiac mortality [7].
MVD can occur in all breeds, but is most prevalent in small to medium-sized dog breeds
such as Cavalier King Charles Spaniels, Dachshund, Miniature Poodle, Maltese, Pomeranian,
Yorkshire Terrier and Chihuahua [8]. One study, recently reported 2 loci weakly associated
with development of MVD by GWAS in the Cavalier King Charles Spaniel breed [9]. Some
over-represented breeds have an incredibly high disease frequency with dogs such as the CKCS
showing>80 affection rates in populations>8yrs of age [10]. A clear problem exists when
considering MVD as a disease amenable to case vs. control genome wide association analysis
(GWAS). It is well documented that canine MVD has age-related penetrance making it difficult
to accurately phenotype an individual as a control. Determining an age cutoff that accurately
predicts MVD development is challenging and provides an imperfect control population hence
underscoring the relative failures of previous techniques [9,11].
In Whippets, previous publications and an ongoing longitudinal study of healthy and MVD
affected dogs have demonstrated high frequency of MVD and a comparably early age of onset
in some dogs supporting its plausible genetic origin [12–14]. The purpose of this study was to
identify a genetic locus associated with the development or severity of MVD inWhippets.
Materials and Methods
Ethics Statement
This study was performed on 138 normal and MVD-affected, client-owned Whippet dogs.
Owner consent was obtained prior to evaluation and blood collection. The University of Cali-
fornia, Davis Animal Care and Use Committee approved the protocol.
Study population, clinical evaluation and disease scoring:
138 Whippet dogs were enrolled in this study as a genetic arm to an ongoing longitudinal
clinical investigation. All dogs received cardiac auscultation, a two-dimensional (2D), M-mode
and Doppler echocardiogram and had 2mL of blood collected in EDTA for future DNA extrac-
tion. Disease phenotype was detailed using results of auscultation and echocardiographic infor-
mation. Heart murmurs were graded as 0-6/6. Cumulative echocardiographic MVD severity
score was calculated for each dog on a scale of 0-6/6. This score was derived based upon the
noted presence or severity of pre-determined echocardiographic findings as noted by the
reporting cardiologist including: mitral valve prolapse, mild mitral valve regurgitation (MR),
and chamber enlargement (left atrium, left ventricle or both; Table 1). An example of how the
scoring system is generated by echocardiogram is demonstrated in Fig 1.
Degenerative valve disease in a highly affected population is a challenging population to
consider the use of standard case vs. control GWAS models. The age-related penetrance of
MVDmakes identification of true control dogs difficult as it is impossible to determine if a
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patient will develop disease if they live long enough. A continuous variable association was con-
sidered and used to take full advantage of the samples available in this study and deal with the
difficulties of age-related penetrance.
A continuous variable was constructed to account for the age-related nature of disease
severity, where younger dogs with MVD would be considered a more severe disease variant
than older dogs with the same level of degenerative change. The age of 5 years was chosen as a
pivotal point in the breed, where dogs less than 5 years demonstrating clear evidence of disease
would be considered the most severely affected animals. To account for age in this construct,
the MVD severity score (made up of discrete variables totaling a maximum of 6 points) was
multiplied by 5 and then divided by the patient’s age in years, yielding a continuous variable.
For example, a 4-year-old dog with a MVD severity score of 4 would be assigned the final con-
tinuous variable value of 5 [(45)/4]. This continuous variable scoring was carried out for each
dog using their age at time of echocardiographic evaluation in years. This scale was derived for
use in this study and the ongoing longitudinal study of MVD in Whippets. To clarify, the mul-
tiplication by 5 in this model produces a linear scaling effect that makes the numbers easier to
manage and understand in a clinical setting and does not affect association results.
Table 1. Cumulative Echocardiographic Score System (Maximum of 6).
Echocardiographic Variable Score
Mitral Valve Prolapse Absent = 0
Mild or Moderate = 1
Severe = 3
Mitral Valve Regurgitation Absent = 0
Mild = 1
Moderate and/or Multiple Jets = 2
Severe = 3
Left Atrial or Ventricular Enlargement Absent = 0
Present = 1
doi:10.1371/journal.pone.0141234.t001
Fig 1. A two-dimensional (A) and two-dimensional with color Doppler (B) echocardiogram from a dog are displayed. The view is left apical four-
chamber showing the left ventricle (LV), left atrium (LA), right ventricle (RV) and right atrium (RA). The mitral valve is denoted by the white arrow in image A.
This image represent a dog with severe mitral valve prolapse as it is observed to buckle back into the LA during systole. Severe mitral valve regurgitation and
chamber enlargement are also apparent, yielding a disease severity score of 6 in this dog.
doi:10.1371/journal.pone.0141234.g001
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The routine echocardiographic technique is standardized as part of an ongoing longitudinal
study of mitral valve degeneration in Whippets. The echocardiographic image acquisition pro-
tocol and measurement methodology is derived from previously described methods [15,16].
Mitral valve regurgitation severity was judged subjectively based upon a color Doppler sur-
face area methodology as previously described [17]. The color Doppler signal was optimized by
adjusting the pulsed repetition frequency to a gain level just below the point where speckle
occurs [17]. Mild mitral valve regurgitation was characterized as a single regurgitant jet with a
regurgitant jet that occupied<30% of the atrium. Moderate regurgitation could include multi-
ple jets and/or a jet that occupied between 30 and 70% of the left atrium. Severe regurgitation
occupied>70% of the left atrium.
Severity of mitral valve prolapse was judged according to Boon [17]. Briefly stated, mild or
moderate prolapse was defined as buckling of either or both of the mitral valve leaflets into the
left atrium beyond the point of the mitral valve annulus. Severe mitral valve prolapse was
defined as bucking of the mitral valve during systole further into the atrium beyond the point
of the dense echogenic area of the lower interatrial septum or atrioventricular junction [17].
Additionally the presence of visible chordae rupture or flail mitral valve leaflets were scored as
severe prolapse.
Blood collection and DNA extraction
DNA was extracted from EDTA blood samples using a commercially available kit (Puregene,
Gentra Systems, Minneapolis, MN), according to the manufacture’s protocol.
Genotyping and quality control:
300ng of high quality (260/280 ratio of 1.8–1.9) DNA was submitted and genotyped using
the 170k Illumina CanineHD BeadChip (Illumina, San Diego, CA). Raw genotype data was
processed for quality control using commercially available software (Golden Helix, Bozeman,
MT, USA) as follows: SNPs were excluded if they had a call rate of< 95% or if they deviated
significantly from Hardy-Weinberg equilibrium (P< 0.001) or if they had low minor allele fre-
quency (< 8%). SNPs residing on the X chromosome were excluded, as there is no indication
for an X-linked pattern of inheritance in the pathogenesis of canine MVD. Individuals were
excluded if either the quantity of isolated DNA was insufficient for the array or the genotyping
rate per individual was<95%.
Genome-wide Association, adjustment for population stratification
Continuous variable association was carried out using commercially available software (Golden
Helix, Bozeman, MT, USA) with the calculated MVD severity score normalized to age as the
phenotypic variable of interest. Multiple testing correction was performed in order to deter-
mine genome wide significance. The robust Bonferroni correction was utilized and genome-
wide significance was set at a P value of 0.05.
A Quantile-Quantile (Q-Q) plot was constructed using observed P-values against expected
P-values. A genome inflation factor (λ) was calculated by dividing median χ2 statistics by 0.456
to assess potential population stratification of the study subjects [18]. The effect of population
stratification was assessed by examining the Q-Q plot for deviation of the p-value from the null
hypothesis. If λ>1, efficient mixed model association expedited (EMMAX) was used to correct
population stratification by applying a kinship matrix and its correction was reevaluated by a
second analysis of the post-EMMAX Q-Q plot and new continuous variable association results
[19].
The SNPs most significantly associated with MVD from the continuous variable analysis
are detailed by location in CanFam 3.1 and test statistics. Any SNP meeting or approaching the
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apriori genome-wide (Bonferroni) significance was investigated for proximity to annotated
genes in CanFam3.1. The described gene function and any published link to cardiac disease in
any species was evaluated and reported.
In order to demonstrate the value of the continuous variable approach, a simple association
using case vs. control methodology was also performed. Cases (n = 26) were described as dogs
with a disease severity score of 3 or greater at any age while controls (n = 20) were dogs with no
evidence of mitral valve regurgitation and an age of at least 5 years.
Results
138 Whippets were prospectively enrolled with 130 remaining for genotype association after
exclusion of inadequate-quality DNA samples and low genotyping rate. Sex distribution of the
remaining 130 dogs was approximately equal with 57 males, 59 females, 1 castrated male and
13 spayed females. The median age was 4.5 years at time of echocardiographic evaluation with
an interquartile range of 2.5 and 7.1 years respectively. The youngest dog evaluated was 1 year
and the oldest 15 years of age. Of 130 dogs the echocardiogram severity score prior to age
indexing was distributed as follows: 83 dogs scored 0; 13 dogs scored 1; 14 dogs scored 2; 10
dogs scored 3; 6 dogs scored 4; 0 dogs scored 5 and 4 dogs scored 6. The distribution of echo-
cardiographic severity score and age is depicted in Fig 2.
A total of 85,196 SNPs and 130 dogs remained for analysis after stringent quality control
and exclusion of the X chromosome. Population stratification was evident based on visual
inspection of the Q-Q plot and λ value = 1.07 (Fig 3A). The use of mixed linear model analysis
was observed to return the Q-Q plot to the expected line and correct the mild population strati-
fication previously observed (Fig 3B). Result of the EMMAX continuous variable, additive
model, association analysis identified a SNP on chromosome 15 (SNP Chr15:58770326, Praw =
5.84E-07, Padjusted = 0.049) that was strongly associated with MVD severity score and genome-
wide significant (Fig 4A). This SNP had a set of tightly clustered SNPs flanking its chromo-
somal location that approach but did not reach genome-wide significance (spanning
Chr15:58506916–60140841 over 8 SNPs; P Praw range of 1.68E-09–1.17E-05, Fig 4B, Table 2).
This region contained multiple annotated genes as denoted in Table 3.
Genotype association analysis identified a secondary tightly clustered region of 5 associated
SNPs on chromosome 2 which were genome-wide suggestive but did not reach Bonferroni sig-
nificance (Chr2:37628875, Chr2:37673511, Chr2:37678327, Chr2:37692930, Chr2:37706121,
all Praw = 9.36E-07 and Padjusted = 0.079, Fig 4C, Table 2). Each of these SNPS was observed to
reside within an intronic region of the ARHGAP26 gene (Table 3).
The case vs. control GWAS did not identify any significant SNPs with disease association.
Discussion
Despite previous attempts, no convincing genome-wide association analysis results exist in
dogs of any breed with MVD. While some reports identified loci associated with MVD, the
phenotyping was questionable as identification of control samples was likely subjected to age-
related errors and the results were not repeatable in other attempts [9, 11]. This is perhaps
because the control subjects were too young to be considered absolute control dogs and their
phenotyping was potentially not as robust as necessary [9, 11]. This historical information
prompted us to develop a protocol by which every dog analyzed could be included in the analy-
sis, thus improving power and reducing the necessity of a case versus control system.
Continuous variable GWAS is frequently used for quantitative traits. While development of
MVD is not quantitative in the strictest sense of the definition, the echocardiographic parame-
ters used to identify MVD are particularly amenable to establishing a scoring system, which
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facilitates this unique approach. Instead of phenotyping perfect control samples that were of
very advanced age without evidence of disease, we elected to identify a genetic component of
MVD linked to disease severity and age of onset. We believe that the high prevalence of this
condition with advanced age, may argue that a causative disease variant is fixed in the breed
and modifier loci may be responsible for observed expressivity differences.
Fig 2. A box and whiskers plot displays the median and range of ages across each severity score
group that was present within this study.
doi:10.1371/journal.pone.0141234.g002
Fig 3. A) Q-Q plot from the continuous variable association with λ = 1.07 demonstrating mild population stratification as seen by the continual deviation from
the line (consistent obtained P values deviate from those which are expected). B) Q-Q plot from the efficient mixed model association expedited (EMMAX)
analysis in which the deviation from expected P values is corrected yielding a single, pronounced deviation from expect P values, consistent with the
significant association results obtained.
doi:10.1371/journal.pone.0141234.g003
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We used findings that we considered supportive of diagnosing MVD and cumulative with
disease severity to build a novel MVD severity score. Age-related penetrance of this condition
necessitated the use of age in the development of the continuous variable. We reviewed data
generated from the echocardiographic screenings and agreed that dogs 5 years of age or less
with evidence of MVD were the most concerning for having a highly penetrant form of MVD.
This age adjustment was also relevant as the median age in the study population. By accounting
for this early age of onset, we developed the equation: (MVD severity score  5) / patient’s age.
A single continuous variable was generated by this equation for each sample and used to associ-
ate severity of MVD with genotype. Considering the novelty of this technique we sought the
Fig 4. A) Manhattan plot demonstrating the genotype association to MVD severity obtained by the mixed linear model, additive, continuous variable analysis
(EMMAX). The most significant regions of interest are noted on chromosome 15 and 2. Raw (Praw) and Bonferroni corrected P values (Padj) are displayed for
the top 2 SNPs. The red lines denote the level of genome wide significance (Bonferroni). B) The same manhattan plot is focused in on a region of
chromosome 15 to demonstrate the flanking region of the most significant SNP. C) The same manhattan plot is focused in on a region of chromosome 2 to
demonstrate the flanking region of the secondary peak of significance.
doi:10.1371/journal.pone.0141234.g004
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strictest criteria for determining genome-wide significance and utilized Bonferroni multiple
testing corrections. Despite the robust correction, a region of significance was successfully
identified.
The value of this approach is underscored by the loss of subjects that would meet inclusion
criteria in the case vs. control GWAS, at least in part due to the confounding age-related pene-
trance. It is further supported by the lack of any significant regions of association in the case vs.
control GWAS.
Clearly defining the severity of the echocardiographic parameters is crucial to the use of the
proposed disease severity score. Parameters that required further definition include the severity
of regurgitation and prolapse. We chose to include variable degrees of MR due to the knowl-
edge that moderate to severe MR can exist in the absence of clinical signs and/or heart enlarge-
ment. This underscores the reasoning for assigning chamber enlargement a separate point on
the disease severity scale [20]. The inclusion of mitral valve prolapse in the severity score is
clinically relevant and multifactorial. In part it is based upon the information that severe mitral
valve prolapse is associated with poor prognosis and thus more severe disease [21]. Addition-
ally, the presence of mitral valve prolapse is present as an early indication of valvular disease in
several breeds of dog [22–24].
Table 2. The SNPsmost significantly association with MVD in the continuous variable EMMAX analy-
sis are detailed by location in CanFam 3.1 and test statistics.
Location Praw-value Padjusted-value
Chr 15: 58770326 5.84E-07 0.049
Chr 2: 37628875 9.36E-07 0.079
Chr 2: 37673511 9.36E-07 0.079
Chr 2: 37678327 9.36E-07 0.079
Chr 2: 37692930 9.36E-07 0.079
Chr 2: 37706121 9.36E-07 0.079
Chr 15: 58976835 1.49E-06 0.12
Chr 15: 59292603 1.68E-09 0.14
Chr 15: 59150571 1.77E-06 0.15
Chr 15: 58506916 2.82E-06 0.24
Chr 15: 59692840 3.15E-06 0.26
Chr 15: 58993573 5.01E-06 0.42
Chr 15: 58472645 7.22E-06 0.61
Chr 15: 60140841 1.17E-05 0.99
doi:10.1371/journal.pone.0141234.t002
Table 3. Positional candidate genes are detailed by the abbreviation, product and location in CanFam3.1.
GENE PRODUCT CANFAM 3.1 LOCATION
FSTL5 follistatin-related protein 5 precursor chr15:57985074–58670763
EEF1a1a eukaryotic translation elongation factor 1 alpha 1 chr15:58853356–58854742
NAF1 H/ACA ribonucleoprotein complex non-core subunit NAF1 isoform a chr15:59429553–59467422
NPY1R neuropeptide Y receptor type 1 chr15:59580561–59583237
NPY5R Neuropeptide Y receptor type 5 chr15:59606935–59608218
TMA16 Translation machinery associated protein chr15:59720507–59750199
March1 E3 ubiquitin-protein ligase MARCH1 chr15:59754467–60036122
ARHGAP26 Rho GTPase-activating protein 26 chr2:37627422–38039759
doi:10.1371/journal.pone.0141234.t003
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Genes of interest were identified within the associated regions on chromosome 15 and
within the suggestive region on chromosome 2. Further evaluation of these genes represents a
possible next step in the molecular evaluation of MVD of Whippets. The positional candidate
gene, FSTL5, has been previously identified as a prognostic marker in human patients with
medulloblastoma [25]. Additionally, it was identified as a positional candidate gene in Irish
Wolfhounds with dilated cardiomyopathy [26]. Although its functional pathway has not been
studied in dogs and is not well elucidated in any species, it is a highly conserved gene from
mammals to zebra fish to chickens. Gene ontology annotations report this gene to be involved
in calcium ion binding (http://amigo.geneontology.org/amigo/term/GO:0005509). Interest-
ingly, STRING10 (http://string-db.org/newstring_cgi/show_network_section.pl) evaluation of
FSTL5 shows a single network connection in dogs to a protein, WFIKKN2 (WAP, follistatin/
kazal, immunoglobulin, kunitz and netrin domain containing 2) that is reported to have meta-
loproteinase inhibition activity. This is of particular interest due to the reported matrix metal-
loproteinase involvement in the pathogenesis of human mitral valve prolapse and canine MVD
[27].
ARHGAP26 (Rho GTPase-activating protein 26) is an activating protein with considerable
interaction at the level of the extracellular matrix. It plays a role in the organization of actin-
cytoskeleton and is expressed in many tissues, including the heart. Gene ontology annotations
report this gene to be involved in phospholipid binding (http://amigo.geneontology.org/
amigo/term/GO:0005543). Interestingly a gene paralog, ARHGAP21, was also identified as a
candidate gene of interest in Irish Wolfhounds with dilated cardiomyopathy. The repeated
overlap of these studies and the multiple hits identified in the evaluation of the cardiomyo-
pathic Wolfhounds may suggest the success of our investigation in identifying genetic compo-
nents of disease severity. Perhaps without intention the DCM loci of interest in this study were
also markers of disease severity or early age of onset [26].
Ultimately this manuscript represents a novel approach to genome wide analysis for cardiac
disease in dogs. The associated regions and positional candidate genes identified warrant fur-
ther investigation through either candidate gene sequencing or next generation sequencing
approaches. The use of GWAS to identify modifier genes or genetic loci associated with disease
severity is a potential way to combat the phenotyping error that plagues studies of acquired dis-
ease of high frequency within the population.
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